Gilead Sciences Q2 Revenue Climbs 8%, Beating Wall Street Forecasts

Gilead Sciences delivered a strong second quarter, with revenue rising 8% year-over-year and beating the average Wall Street forecast. The primary growth driver remains its HIV treatment and prevention portfolio, which continues to generate steady cash flow for the company. The positive momentum was also supported by an expanding oncology drug lineup and other therapeutic areas. The strong results reinforce Gilead's position as one of the more stable players in the biopharma sector amid volatility among riskier biotech names. Investors took the earnings beat as a sign of management's confidence in sustaining growth through the second half of the year.